ELV

ELV

USD

Elevance Health Inc. Common Stock

$409.980-2.320 (-0.563%)

Цена в режиме реального времени

Healthcare
Healthcare Plans
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$412.300

Максимум

$413.100

Минимум

$406.550

Объем

0.14M

Фундаментальные показатели компании

Рыночная капитализация

92.6B

Отрасль

Healthcare Plans

Страна

United States

Статистические данные торговли

Средний объем

1.66M

Биржа

NYQ

Валюта

USD

52-недельный диапазон

Минимум $362.21Текущая $409.980Максимум $567.26

Отчет об анализе ИИ

Последнее обновление: 21 апр. 2025 г.
Сгенерировано ИИИсточник данных: Yahoo Finance, Bloomberg, SEC

[ELV: Elevance Health Inc. Common Stock]: Navigating Healthcare Headwinds - What's Next?

Stock Symbol: ELV Generate Date: 2025-04-21 08:32:13

Alright, let's dive into what's happening with Elevance Health (ELV). It's been a bit of a rollercoaster lately, and there are a few key things to unpack to understand where this stock might be headed.

Recent News Buzz: A Cloud of Concern

The overall feeling in the news lately? Definitely leaning towards cautious, maybe even a bit negative. The big story isn't directly about Elevance yet, but it's casting a shadow. Think of it like this: if the biggest kid on the block, UnitedHealth, suddenly stumbles and says things are getting tougher, everyone else in the neighborhood pays attention.

Specifically, UnitedHealth – usually seen as super reliable – just warned that their profits are going to be lower than expected. Why? Because medical costs are climbing, and people are using healthcare services more than anticipated. This is a big deal because UnitedHealth is considered a bellwether for the entire health insurance industry. So, when they feel the pinch, it often means others will too.

This news has analysts rethinking things. Baird, for example, just downgraded Elevance Health from a "Buy" to a "Neutral" rating and lowered their price target. That's analyst-speak for "we're not as optimistic as we were." They're basically saying Elevance might face similar cost pressures as UnitedHealth.

Now, it's not all doom and gloom. Before this UnitedHealth news hit, several other analysts (Truist, Guggenheim, Mizuho) actually raised their price targets for Elevance and kept "Buy" or "Outperform" ratings. This suggests there's still underlying confidence in the company's potential. But the recent UnitedHealth news definitely throws a wrench into the works and makes those earlier positive notes feel a bit outdated.

Price Check: A Recent Dip, But Where to From Here?

Looking at the stock price over the last month or so, it's been a bit of a mixed bag. We saw a pretty solid climb through February and into early March. Then, things got choppy. And then, bam! On April 17th, the stock price took a significant tumble. No surprise there, given the UnitedHealth news broke around that time.

Before that drop, ELV was hanging around the $430-$440 range. After the news, it plunged down to around $390. That's a pretty sharp move. Currently, we're looking at a price around that $390 mark (based on the last data point of $390.00 on 2025-04-17).

Now, what's interesting is what the AI is predicting. It's forecasting further downward pressure for today and the next couple of days. They're talking about percentage drops each day. This lines up with the negative news sentiment and the recent price drop. It suggests the AI sees this downward trend continuing in the very short term.

Outlook & Ideas: Patience Might Be the Play

Putting it all together, what's the vibe for Elevance Health right now? It feels like caution is the name of the game. The negative news around UnitedHealth and rising healthcare costs is a real concern for the entire sector, and Elevance won't be immune. The recent price drop reflects this worry, and the AI predictions suggest more of the same in the immediate future.

Does this mean "sell"? Not necessarily. It's more like a "hold" or "wait-and-see" situation. Those earlier positive analyst ratings are still out there, and they highlight the underlying strengths of Elevance. Plus, the recommendation data, while mixed, does point to some bullish technical indicators and strong analyst sentiment overall (though this might be pre-UnitedHealth news impact).

Potential Entry Consideration? If you were thinking about buying ELV, now might not be the time to jump in headfirst. The AI prediction suggests further dips. A potential strategy could be to watch for a possible stabilization point. Maybe around the $375-$380 range? The AI prediction mentions a support level around $376.60. If the price drifts down towards that level and shows signs of bouncing back, that might be an interesting area to consider a small entry, but only if you're comfortable with short-term trading and understand the risks.

Potential Exit/Stop-Loss Consideration? If you already own ELV, it really depends on your risk tolerance and investment timeframe. If you're a short-term trader, you might be considering taking some profits or cutting losses after this recent drop. A potential stop-loss level could be placed below recent lows, perhaps around $380 or even a bit lower, to protect against further downside if the negative trend continues. For longer-term investors, it might be about weathering the storm and seeing how Elevance navigates these industry headwinds.

Company Context Reminder: Elevance Health is a major player in health benefits. So, news about healthcare costs and industry trends directly impacts their business. Keep an eye on their upcoming earnings call on April 22nd. That's when we'll get a much clearer picture of how they're actually performing and what they expect for the rest of the year. What they say about costs and their outlook will be crucial.

In short: Elevance Health is facing some industry-wide challenges right now. The recent news and price action suggest caution. Keep a close watch on upcoming company news and broader healthcare trends before making any big moves.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. The stock market is inherently risky, and prices can fluctuate. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Связанные новости

Reuters

US files false claims complaint against three health insurers

The U.S. Justice Department on Thursday said it had filed a complaint against three of the country's biggest health insurance companies, Aetna Inc. and affiliates, Elevance Health and Humana , under the False Claims Act.

Просмотреть больше
US files false claims complaint against three health insurers
Reuters

Corporate America boosts security spending after UnitedHealth murder, filings show

U.S. corporations have been ramping up their security spending, but following the murder of UnitedHealth executive Brian Thompson that expenditure is set to rise further in 2025 as more companies see heightened threats to their top brass.

Просмотреть больше
Corporate America boosts security spending after UnitedHealth murder, filings show
Analyst Upgrades

RBC Capital Reiterates Outperform on Elevance Health, Maintains $478 Price Target

RBC Capital analyst Ben Hendrix reiterates Elevance Health with a Outperform and maintains $478 price target.

Просмотреть больше
RBC Capital Reiterates Outperform on Elevance Health, Maintains $478 Price Target
Analyst Upgrades

Guggenheim Reiterates Buy on Elevance Health, Maintains $518 Price Target

Guggenheim analyst Jason Cassorla reiterates Elevance Health with a Buy and maintains $518 price target.

Просмотреть больше
Guggenheim Reiterates Buy on Elevance Health, Maintains $518 Price Target
Analyst Upgrades

Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $485 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Elevance Health with a Overweight and maintains $485 price target.

Просмотреть больше
Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $485 Price Target
Analyst Upgrades

Barclays Maintains Overweight on Elevance Health, Raises Price Target to $522

Barclays analyst Andrew Mok maintains Elevance Health with a Overweight and raises the price target from $512 to $522.

CNBC

Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Прогноз ИИBeta

Рекомендация ИИ

Медвежий

Обновлено в: 3 мая 2025 г., 21:30

МедвежийНейтральныйБычий

63.6% Уверенность

Риск и торговля

Уровень риска1/5
Низкий риск
Подходит для
Консервативный
Руководство по торговле

Точка входа

$408.19

Взять прибыль

$418.04

Остановить убытки

$393.61

Ключевые факторы

PDI 5.6 выше MDI 5.2 с ADX 12.6, что предполагает бычий тренд
Текущая цена очень близка к уровню поддержки ($409.26), что предполагает сильную возможность покупки
Объем торгов в 4.5 раз превышает среднее значение (18,232), что указывает на чрезвычайно сильное покупательское давление
MACD 0.2875 выше сигнальной линии 0.2025, что указывает на бычье пересечение

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.